Exhibit 99.1
AMENDED AND RESTATED TERM SHEET
This Amended and Restated Term Sheet (this “Amended and Restated Term Sheet”) is made and entered into by and among HANMI FINANCIAL CORPORATION, a Delaware corporation and registered bank holding company with its principal offices in Los Angeles, California (the “Company”), LEADING INVESTMENT & SECURITIES CO., LTD., a Korean corporation with its principal offices in Seoul, Korea (“Leading”) and IWL PARTNERS LLC, a Korean company with its principal offices in Seoul, Korea (“IWL Partners,” and collectively with the Company and Leading, the “Parties”).
WHEREAS, the Parties hereto have amended a Term Sheet dated as of May 28, 2009 (the “Term Sheet”) on August 5, 2009, outlining the terms and conditions of the proposed investments by Leading and IWL in newly issued common stock of the Company;
WHEREAS, the Company and Leading entered into a Securities Purchase Agreement (the “SPA”) dated as of June 12, 2009 pursuant to which the Company has agreed to issue and Leading has agreed to purchase certain number of shares of the common stock of the Company, as contemplated by the Term Sheet;
WHEREAS, the Company and Leading have subsequently amended the SPA on July 31, 2009 to, among others, extend the closing date of the Leading Investment and Additional Leading Investment to September 30, 2009; and
WHEREAS, the Company and Leading have consummated the Leading Investment (as defined below) as of September 4, 2009.
NOW, THEREFORE, in consideration of the mutual covenants contained in this Amended and Restated Term Sheet, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree to amend and restate the Term Sheet, as amended, as follows:
Section A. Introduction
| | | | |
Transactions | | Leading will purchase: |
| | |
| | (i) | | shares of newly issued common stock of the Company in an amount equal to 9.9% of the total outstanding common stock of the Company on a fully diluted basis at a price per share equal to $1.37 (the “Leading Investment”); and |
| | |
| | (ii) | | shares of newly issued common stock of the Company in an amount, which together with the Leading Investment, will equal to 14.9% of the total outstanding common stock of the Company on a fully diluted basis at a price per share equal to $1.37 (the “Additional Leading Investment”), subject to receipt of the regulatory approval and/or confirmation described in the section of this Amended and Restated Term Sheet entitled “Leading |